The impact of right ventricular function on prognosis in patients with stage III non-small cell lung cancer after concurrent chemoradiotherapy

被引:0
|
作者
Lu Chen
Jingjuan Huang
Weihua Wu
Shengjun Ta
Xiaoyi Xie
机构
[1] Shanghai Chest Hospital,Department of Ultrasound
[2] Shanghai Jiao Tong University,Department of Cardiology
[3] Shanghai Chest Hospital,Department of Ultrasound
[4] Shanghai Jiao Tong University,undefined
[5] Yan’an People’s Hospital,undefined
来源
The International Journal of Cardiovascular Imaging | 2019年 / 35卷
关键词
Right ventricle; Strain; Chemoradiotherapy; Non-small cell lung cancer;
D O I
暂无
中图分类号
学科分类号
摘要
Right ventricular (RV) impairment after cancer therapy-related cardiotoxicity and its prognostic implications in lung cancer have not been examined. The present research sought to evaluate RV structure, function, and mechanics in stage III non-small-cell lung cancer (NSCLC) before and after concurrent chemoradiotherapy (CCRT), and to explore the associations between RV impairments, radiation dose, and all-cause mortality. This prospective investigation included 128 inoperable NSCLC patients who were scheduled to receive CCRT. Echocardiographic examination and strain evaluation was performed at baseline and 6 months post-CCRT in all participants. Conventional RV dimensions revealed no significant changes post-CCRT. However, a reduction in RV free wall strain (RV-fwLS) was observed at 6 months post-CCRT (− 28.3 ± 4.6% vs. − 25.5 ± 4.8%, P < 0.001). The same was revealed for global RV longitudinal strain (RV-GLS) (− 23.4 ± 2.9% vs. − 20.2 ± 3.4%, P < 0.001). Pearson correlation showed that RV radiation mean dose was related with the percentage change in RV-fwLS (r = 0.303, P = 0.001) and RV-GLS (r = 0.284, P = 0.002). In multivariable analysis, the percentage change in RV-fwLS was an independent predictor of all-cause mortality (HR 1.296, 95% CI 1.202–1.428, P < 0.001). RV longitudinal strain is deteriorated at 6 months post-CCRT. The RV mechanics deterioration was associated with radiation dose and affected the long-term outcome of stage III NSCLC patients treated with CCRT.
引用
收藏
页码:1009 / 1017
页数:8
相关论文
共 50 条
  • [1] The impact of right ventricular function on prognosis in patients with stage III non-small cell lung cancer after concurrent chemoradiotherapy
    Chen, Lu
    Huang, Jingjuan
    Wu, Weihua
    Ta, Shengjun
    Xie, Xiaoyi
    INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING, 2019, 35 (06) : 1009 - 1017
  • [2] Outcomes of Concurrent Chemoradiotherapy in Elderly Patients with Stage III Non-Small Cell Lung Cancer
    Lee, Seok Ho
    Lee, Seung Heon
    Heo, Ho-Jin
    Sung, Kihoon
    Lee, Kyu Chan
    Jung, Sung Hwan
    Park, Jeong Woong
    Cho, Eun Kyung
    Ahn, Hee Kyung
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S685 - S685
  • [3] Determinants of Sequential versus Concurrent Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer Patients
    Walraven, Iris
    Ten Berge, M.
    Damhuis, Ronald
    Tissing-Tan, C.
    Troost, E.
    Reymen, B.
    Widder, J.
    Koppe, F.
    Van Der Wel, A.
    Vonk, E.
    Coremans, I.
    Bussink, J.
    De Jaeger, K.
    Van Zyp, N. Van Der Voort
    El Sharouni, Sherif
    Knol, H.
    Woutersen, D.
    Belderbos, Jose
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S539 - S539
  • [4] Weight loss predicts poor prognosis in patients treated with concurrent chemoradiotherapy for stage III non-small cell lung cancer
    Wei, Min
    Xie, Conghua
    BIOMEDICAL RESEARCH-INDIA, 2017, 28 (14): : 6308 - 6313
  • [5] Effect analysis of chemoradiotherapy after operation in patients with stage III A non-small cell lung cancer
    Chen, Sheng
    Cheng, Yu-Ling
    Li, Shi-Ting
    Ni, Yao-Jun
    Gu, Biao
    ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE, 2012, 5 (10) : 823 - 827
  • [6] Effect of Interstitial Lung Abnormality on Concurrent Chemoradiotherapy-treated Stage III Non-small Cell Lung Cancer Patients
    Jeong, Won Gi
    Kim, Yun-Hyeon
    Ahn, Sung-Ja
    Jeong, Jae-Uk
    Lee, Byung Chan
    Cho, Ick Joon
    Kim, Yong-Hyub
    ANTICANCER RESEARCH, 2023, 43 (04) : 1797 - 1807
  • [7] Early recurrence factors in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy
    Takahara, Yutaka
    Tanaka, Takuya
    Ishige, Yoko
    Shionoya, Ikuyo
    Yamamura, Kouichi
    Sakuma, Takashi
    Nishiki, Kazuaki
    Nakase, Keisuke
    Nojiri, Masafumi
    Kato, Ryo
    Shinomiya, Shohei
    Oikawa, Taku
    Mizuno, Shiro
    THORACIC CANCER, 2022, 13 (24) : 3451 - 3458
  • [8] Concurrent sintilimab with sequential chemoradiotherapy for unresectable, stage III non-small cell lung cancer: a retrospective study
    Tang, Shi
    Cong, Xiaofeng
    Zheng, Dan
    Chen, Chen
    Liu, Zengguang
    Gao, Jie
    Zhang, Huimin
    Zhang, Youhao
    Liu, Ziling
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [9] EFFICACY AND SAFETY OF CONCURRENT CHEMORADIOTHERAPY IN ELDERLY PATIENTS WITH UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER: A RETROSPECTIVE STUDY
    Boku, Shogen
    Kasamatsu, Yu
    Yoshinoya, Kiyokazu
    Kida, Takashi
    Izumi, Hiroyuki
    Ushijima, Yo
    Kasamatsu, Yoshihiro
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S487 - S487
  • [10] Gender Difference in Treatment Outcomes in Patients with Stage III Non-small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy
    Sekine, Ikuo
    Sumi, Minako
    Ito, Yoshinori
    Tanai, Chiharu
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Kunitoh, Hideo
    Ohe, Yuichiro
    Tamura, Tomohide
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2009, 39 (11) : 707 - 712